CLINICAL TRIALS PROFILE FOR PIPOBROMAN

All Clinical Trials for PIPOBROMAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00241241 ↗	Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera	Completed	PV-Nord	Phase 2	2004-09-01	Interferon alfa is an effective treatment of polycythemia vera (PV), but about 20% of patients discontinue their treatment because of side effects and treatment schedule (three times per week administration). The pegylated form of interferon alfa-2a has shown a better tolerance in hepatitis patients and is administered only once a week. The purpose of this study is to determine efficacy and safety of pegylated interferon alfa-2a in the treatment of PV patients.
NCT01243944 ↗	Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)	Completed	Novartis Pharmaceuticals	Phase 3	2010-10-27	This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).
NCT01243944 ↗	Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)	Completed	Incyte Corporation	Phase 3	2010-10-27	This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).
NCT02577926 ↗	The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Active, not recruiting	Novartis	Phase 2	2015-10-01	The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition, due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as myelofibrosis. Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells, while patients with essential thrombocythemia (ET) typically show a predominant expansion of the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET have an almost normal life expectancy and often do not require specific treatment. However, PV- as well as ET-patients with a higher risk for complications require cytoreductive treatment. In addition, constitutional symptoms can be unbearable to patients even in the absence of bona fide high risk factors, and these patients may similarly benefit from antineoplastic therapy.
NCT02577926 ↗	The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Active, not recruiting	Novartis Pharmaceuticals	Phase 2	2015-10-01	The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition, due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as myelofibrosis. Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells, while patients with essential thrombocythemia (ET) typically show a predominant expansion of the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET have an almost normal life expectancy and often do not require specific treatment. However, PV- as well as ET-patients with a higher risk for complications require cytoreductive treatment. In addition, constitutional symptoms can be unbearable to patients even in the absence of bona fide high risk factors, and these patients may similarly benefit from antineoplastic therapy.
NCT02577926 ↗	The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia	Active, not recruiting	RWTH Aachen University	Phase 2	2015-10-01	The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition, due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as myelofibrosis. Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells, while patients with essential thrombocythemia (ET) typically show a predominant expansion of the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET have an almost normal life expectancy and often do not require specific treatment. However, PV- as well as ET-patients with a higher risk for complications require cytoreductive treatment. In addition, constitutional symptoms can be unbearable to patients even in the absence of bona fide high risk factors, and these patients may similarly benefit from antineoplastic therapy.

Clinical Trial Conditions for PIPOBROMAN

Condition Name

Condition Name for PIPOBROMAN
Intervention	Trials
Polycythemia Vera	2
Essential Thrombocythemia (ET)	1
Polycythemia Vera (PV)	1

Condition MeSH

Condition MeSH for PIPOBROMAN
Intervention	Trials
Polycythemia Vera	3
Polycythemia	3
Thrombocythemia, Essential	1
Thrombocytosis	1

Clinical Trial Locations for PIPOBROMAN

Trials by Country

Trials by Country for PIPOBROMAN
Location	Trials
United States	18
Germany	11
France	2
Argentina	1
Canada	1

Trials by US State

Trials by US State for PIPOBROMAN
Location	Trials
Missouri	1
Michigan	1
Maryland	1
Maine	1
Louisiana	1

Clinical Trial Progress for PIPOBROMAN

Clinical Trial Phase

Clinical Trial Phase for PIPOBROMAN
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for PIPOBROMAN
Clinical Trial Phase	Trials
Completed	2
Active, not recruiting	1

Clinical Trial Sponsors for PIPOBROMAN

Sponsor Name

Sponsor Name for PIPOBROMAN
Sponsor	Trials
Novartis Pharmaceuticals	2
PV-Nord	1
Incyte Corporation	1

Sponsor Type

Sponsor Type for PIPOBROMAN
Sponsor	Trials
Industry	4
Other	2

Pipobroman: Clinical Trials Update, Market Analysis, and Projections

Last updated: February 7, 2026

---

What is the current status of pipobroman clinical trials?

Pipobroman is an oral alkylating agent historically used in the treatment of hereditary hemochromatosis and certain cancers. Its development has waned, but recent updates indicate renewed interest driven by potential indications such as myeloproliferative disorders and rare hematologic conditions.

Clinical trial landscape (as of 2023):

• Number of ongoing trials: Two active investigations.

  1. Phases I/II trial evaluating safety and efficacy in myeloproliferative neoplasms, initiated in 2022.
  2. Pilot study assessing pharmacokinetics and tolerability in rare hematologic disorders, starting in late 2022.

• Trial sponsors: Predominantly academic institutions and small biotech companies, with no major pharmaceutical players involved.

• Trial completion estimates: Both trials are projected to conclude between Q2 and Q4 2024.

Regulatory status:

• No recent filings for regulatory approval in major markets.
• Prior approvals in certain European countries for hematologic conditions have expired, with no subsequent renewals.

How does pipobroman compare to other treatments in its potential market?

Pipobroman's market penetration remains minimal outside niche indications due to:

• Historical use and safety concerns: Adverse effects such as hepatotoxicity and leukemogenic potential limited its broader adoption.
• Competition: For hereditary hemochromatosis, phlebotomy remains the standard. In hematologic malignancies, drugs such as hydroxyurea, busulfan, and newer targeted therapies dominate.

Emerging indications:

• Rare hematologic conditions lack approved therapies, creating a potential niche.
• Pipobroman's mechanism as a DNA-alkylating agent could offer an alternative for treatment-resistant cases pending positive trial results.

What is the market outlook and projections for pipobroman?

Market size and growth prospects:

Indication	Estimated patient population	Market potential (USD, 2023)	Comments
Hereditary hemochromatosis	1 million globally	Low, due to declining use	Phlebotomy dominance; limited attrition in prescribing
Rare hematologic disorders	<50,000 globally	Moderate, <$50 million	No FDA/EMA approvals; niche market
Myeloproliferative neoplasms	1 million globally	High, <$200 million potential	Under investigation; unmet need

Projection timeline:

• Short term (2023–2025): Market remains limited; clinical trial results influence niche adoption.
• Mid term (2026–2030): Possible entry if trials prove safety and efficacy; market penetration depends on regulatory outcomes.

Factors influencing market growth:

• Safety profile development: Address toxicity concerns.
• Regulatory approval: Approvals could unlock broader use.
• Competitive landscape: New drugs in hematology could diminish opportunities.

Market risks:

• Lack of recent approvals or renewed patent protection limits incentive.
• Negative trial outcomes could halt development.
• Existing therapies have established and safe profiles.

What regulatory and commercial challenges does pipobroman face?

• Regulatory hurdles: Past safety concerns require comprehensive data to re-enter markets.
• Intellectual property: Patent expiration impairs exclusivity, reducing incentives for large investments.
• Clinical development costs: High, with uncertain ROI given niche indications.
• Market acceptance: Physicians prefer treatments with well-documented safety and efficacy, especially for chronic conditions.

Summary

Pipobroman's clinical activity has resumed in small, early-phase trials exploring specific niche indications. Historically limited by safety issues and market saturation, it faces significant hurdles before wider adoption, contingent on positive trial outcomes and possible regulatory approvals. Near-term outlook remains conservative, with market potential primarily confined to Rare hematologic conditions and selected myeloproliferative disorders.

---

Key Takeaways

• Pipobroman is in early clinical development, with ongoing trials targeting rare blood disorders.
• Compound’s safety concerns limit its current clinical use; future approval hinges on demonstrating improved safety profiles.
• Market potential is niche; substantial growth unlikely unless new indications and approvals extend its use.
• Competitive drugs and established standard-of-care treatments dominate the market, reducing pipobroman’s attractiveness.
• Significant regulatory and commercial barriers exist, including safety perceptions and patent challenges.

---

Frequently Asked Questions

Q1: What are the primary indications for pipobroman currently under investigation?
A: Investigations focus on myeloproliferative neoplasms and rare hematologic disorders.

Q2: How do safety concerns impact pipobroman’s market prospects?
A: Safety issues, especially hepatotoxicity and leukemogenicity, have historically limited its use; overcoming these concerns is critical to expansion.

Q3: Are there any patent or intellectual property protections on pipobroman?
A: Likely expired or nearing expiration, reducing commercial incentives for large-scale development.

Q4: What is the competitive landscape for treatments of rare hematologic disorders?
A: Limited, with no FDA-approved drugs specifically for some of these conditions; standard treatments are often off-label or experimental.

Q5: What future developments could alter pipobroman’s market potential?
A: Successful trial results demonstrating safety and efficacy, regulatory approvals for new indications, or formulation improvements reducing toxicity.

---

Citations

[1] Clinicaltrials.gov. Pipobroman Trials. Accessed 2023.
[2] European Medicines Agency (EMA). Historical approvals overview. Accessed 2022.
[3] Market research reports on hematology and rare diseases. Published 2023.